- Home
- LDWY vs CANF Comparison
LDWY vs CANF Comparison
Compare LDWY & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDWY
- CANF
- Stock Information
- Founded
- LDWY 1990
- CANF 1994
- Country
- LDWY United States
- CANF Israel
- Employees
- LDWY N/A
- CANF N/A
- Industry
- LDWY Advertising
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- LDWY Consumer Discretionary
- CANF Health Care
- Exchange
- LDWY Nasdaq
- CANF Nasdaq
- Market Cap
- LDWY 6.7M
- CANF 7.9M
- IPO Year
- LDWY 1991
- CANF N/A
- Fundamental
- Price
- LDWY $4.12
- CANF $1.17
- Analyst Decision
- LDWY
- CANF Strong Buy
- Analyst Count
- LDWY 0
- CANF 2
- Target Price
- LDWY N/A
- CANF $14.00
- AVG Volume (30 Days)
- LDWY 3.9K
- CANF 412.3K
- Earning Date
- LDWY 05-19-2025
- CANF 05-06-2025
- Dividend Yield
- LDWY N/A
- CANF N/A
- EPS Growth
- LDWY N/A
- CANF N/A
- EPS
- LDWY N/A
- CANF N/A
- Revenue
- LDWY $37,773,000.00
- CANF $674,000.00
- Revenue This Year
- LDWY N/A
- CANF $461.72
- Revenue Next Year
- LDWY N/A
- CANF N/A
- P/E Ratio
- LDWY N/A
- CANF N/A
- Revenue Growth
- LDWY N/A
- CANF N/A
- 52 Week Low
- LDWY $3.02
- CANF $1.22
- 52 Week High
- LDWY $6.44
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- LDWY 62.30
- CANF 37.12
- Support Level
- LDWY $3.70
- CANF $1.14
- Resistance Level
- LDWY $4.23
- CANF $1.27
- Average True Range (ATR)
- LDWY 0.18
- CANF 0.12
- MACD
- LDWY 0.05
- CANF -0.02
- Stochastic Oscillator
- LDWY 56.24
- CANF 4.46
About LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two Industry Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).